After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Beam Therapeutics Inc is $1.73B. A total of 1.98 million shares were traded on the day, compared to an average of 2.07M shares.
In the most recent transaction, Bellon Christine sold 5,674 shares of BEAM for 18.35 per share on Apr 01 ’25. After the transaction, the Chief Legal Officer now owns 117,294 company shares. In a previous transaction on Apr 01 ’25, Evans John M. sold 30,663 shares at 18.35 per share. BEAM shares that CEO owns now total 986,249.
Among the insiders who sold shares, Ciaramella Giuseppe disposed of 7,434 shares on Apr 01 ’25 at a per-share price of $18.35. This resulted in the President holding 190,216 shares of BEAM after the transaction. In another insider transaction, Cavanagh Bethany J sold 3,015 shares at $18.35 per share on Apr 01 ’25. Company shares held by the SVP, Finance and Treasurer now total 44,512.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, BEAM has a high of $35.25 and a low of $13.52.
As of this writing, BEAM has an earnings estimate of -$1.17 per share for the current quarter. EPS was calculated based on a consensus of 14.0 estimates, with a high estimate of -$0.7 per share and a lower estimate of -$1.47.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BEAM’s latest balance sheet shows that the firm has $965.65M in Cash & Short Term Investments as of fiscal 2021. There were $142.35M in debt and $213.44M in liabilities at the time. Its Book Value Per Share was $8.77, while its Total Shareholder’s Equity was $826.74M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BEAM is Buy with a score of 4.65.
